Company intelligence / Profile preview

Delta-Fly Pharma, Inc.

Kawauchi-cho, Tokushima, Japandelta-flypharma.co.jp ↗

Ownership: Private
Employees: ~13
Development stage: Phase 3

Overview

The company has multiple programs in clinical development, with DFP-10917 in Phase III clinical trial in the US and Phase I in Japan for relapsed/refractory acute myeloid leukemia, DFP-14323 in Phase III for lung cancer, DFP-17729 in Phase I/II for solid cancer and recently starting Phase 2/3 for pancreatic cancer, DFP-11207 completed Phase I for pancreatic cancer, DFP-14927 in Phase I for hematologic cancer, and DFP-10825 in preclinical trials for gastric/ovarian cancer

Therapeutic areas: HematologyOncology
Modalities: Small molecules (anticancer drugs)
Industry: Biotech

Drug pipeline

5 assets

radgocitabine

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Delta-Fly Pharma, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Delta-Fly Pharma, Inc..

Explore the full profile